SystImmune’s BL-M14D1 Shows Strong Activity in SCLC
REDMOND, Wash., June 1, 2026 SystImmune has reported encouraging Phase 1 clinical data for its investigational DLL3-targeting antibody-drug conjugate...
neuroendocrine carcinoma
Advertisement
Leads Biolabs Wins Phase III Approval for Opamtistomig in Advanced EP-NEC
NANJING, China, May 18, 2026 Leads Biolabs announced that its proprietary PD-L1/4-1BB bispecific antibody Opamtistomig (LBL-024) has received approval...
Boehringer Ingelheim, Zai Lab Advance DLL3 Cancer Trial
Ingelheim, Germany & Shanghai, China | April 15, 2026 Boehringer Ingelheim and Zai Lab have announced a strategic clinical...
Advertisement
